To view all resources for this episode, view the episode page HERE:
Description:
This episode of SOHO Spotlight explores the evolving role of CD19 CAR T-cell therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), highlighting the importance of early referral, patient selection criteria, and differences between currently available CAR T products. Dr. Jae Park and Dr. Nicholas Short discuss emerging evidence supporting safer outpatient treatment, individualized decisions regarding stem cell transplant after CAR T therapy, and the potential for CAR T to move into earlier lines of treatment, with the goal of improving long-term outcomes while reducing the need for intensive chemotherapy and transplantation.
Host
Nicholas J. Short, MD
Associate Professor
MD Anderson Cancer Center
Houston, Texas, USA
Dr. Nicholas J. Short is an Associate Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center. He is a nationally recognized leukemia specialist whose research focuses on acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), measurable residual disease (MRD), and the development of novel immunotherapy-based treatments.
Connect with Dr. Short:
- Website
- LinkedIn
- Twitter/X
Guest Speaker:
Jae Park, MD
Chief, Cellular Therapy Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York, USA
Dr. Jae Park is Chief of the Cellular Therapy Service and Director of the Adult Acute Lymphoblastic Leukemia Program at Memorial Sloan Kettering Cancer Center. An internationally recognized expert in cellular therapies and immunotherapy for hematologic malignancies, his research focuses on developing safer and more effective CAR T-cell therapies to improve outcomes for patients with leukemia.
Connect With Us
• SUBSCRIBE
- SOHOSPOTLIGHT
- HOME
- Newsletter
- Social:
- YouTube
- Facebook
- Twitter
- LinkedIn
- Instagram
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Society of Hematologic Oncology.
